Based on the Esperion Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Esperion Therapeutics Inc is USD 9.70 over the next 12 months. Esperion Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Esperion Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Esperion Therapeutics Inc’s stock price was USD 2.21. Esperion Therapeutics Inc’s stock price has changed by +3.76% over the past week, +2.31% over the past month and +114.56% over the last year.
No recent analyst target price found for Esperion Therapeutics Inc
No recent average analyst rating found for Esperion Therapeutics Inc
Company Overview Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Read Less
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe...Read More
Frequently Asked Questions About Esperion Therapeutics Inc (ESPR) Stock
Based on ratings from 3 analysts Esperion Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, 1 sell and hold ratings.
Unfortunately we do not have enough data on ESPR's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ESPR is USD 9.70 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 2.5.
Unfortunately we do not have enough data on ESPR's stock to indicate if its overvalued.
The last closing price of ESPR's stock was USD 2.21.
The most recent market capitalization for ESPR is USD 0.40B.
Based on targets from 3 analysts, the average taret price for ESPR is projected at USD 9.70 over the next 12 months.
This means that ESPR's stock price may go up by +338.91% over the next 12 months.
We can't find any ETFs which contains Esperion Therapeutics Inc's stock.
As per our most recent records Esperion Therapeutics Inc has 240 Employees.
Esperion Therapeutics Inc's registered address is 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108.
You can get more information about it from Esperion Therapeutics Inc's website at https://www.esperion.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Esperion Therapeutics Inc (ESPR) Stock
Based on ratings from 3 analysts Esperion Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, 1 sell and hold ratings.
Unfortunately we do not have enough data on ESPR's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ESPR is USD 9.70 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 2.5.
Unfortunately we do not have enough data on ESPR's stock to indicate if its overvalued.
The last closing price of ESPR's stock was USD 2.21.
The most recent market capitalization for ESPR is USD 0.40B.
Based on targets from 3 analysts, the average taret price for ESPR is projected at USD 9.70 over the next 12 months.
This means that ESPR's stock price may go up by +338.91% over the next 12 months.
We can't find any ETFs which contains Esperion Therapeutics Inc's stock.
As per our most recent records Esperion Therapeutics Inc has 240 Employees.
Esperion Therapeutics Inc's registered address is 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108.
You can get more information about it from Esperion Therapeutics Inc's website at https://www.esperion.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ESPR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
